Cargando…

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer worldwide. Not long ago, before the introduction of ICIs, many cancers incurred a grave prognosis on patients due to the lack of effective therapies. For instance, patients with malignant melanoma survive longer and exper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellithi, Moataz, Elnair, Radowan, Chang, Guy Vin, Abdallah, Mohamed A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067353/ https://www.ncbi.nlm.nih.gov/pubmed/32190487 http://dx.doi.org/10.7759/cureus.6935

Ejemplares similares

Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib
por: Elnair, Radowan, et al.
Publicado: (2018)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

iTi Conference in Turbulence 2018
por: Örlü, Ramis, et al.
Publicado: (2019)

6th iTi Conference
por: Peinke, Joachim, et al.
Publicado: (2016)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

7th iTi Conference in Turbulence
por: Örlü, Ramis, et al.
Publicado: (2017)

4th iTi Conference in Turbulence
por: Oberlack, Martin, et al.
Publicado: (2012)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Park, Robin, et al.
Publicado: (2020)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
por: Snyder, Gretchen L., et al.
Publicado: (2016)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

5th iTi Conference in Turbulence 2012
por: Talamelli, Alessandro, et al.
Publicado: (2014)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2021)

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
por: Zou, Defang, et al.
Publicado: (2023)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
por: Verheijden, Rik J, et al.
Publicado: (2020)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
por: Johns, Andrew C, et al.
Publicado: (2023)

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
por: Reul, Johanna, et al.
Publicado: (2019)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

ITI Conference 2 : translators and interpreters mean business : proceedings of the second annual conference of the Institute of Translation and Interpreting, 29-30 April 1988, Hotel Russell, London
Publicado: (1988)

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
por: Yang, Wenhan, et al.
Publicado: (2020)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
por: Fan, Yong, et al.
Publicado: (2021)

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events
por: Zeng, Yanlin, et al.
Publicado: (2023)

Ity'an yik'oty iñatyibal ajCHolo' = Voz y conocimiento del pueblo CH'ol /
por: Guzmán López, Hilda
Publicado: (2013)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study
por: Hu, Yizhang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hb912dt00g48g46o1qcv542eua